NLS Pharmaceutics Shares Are Trading Higher After the Company Announced Preclinical Data for Its Non-sulfonamide, Dual Orexin Receptor Agonists for Potential Treatment of Narcolepsy and Neurological Disorders.
NLS Pharmaceutics Shares Are Trading Higher After the Company Announced Preclinical Data for Its Non-sulfonamide, Dual Orexin Receptor Agonists for Potential Treatment of Narcolepsy and Neurological Disorders.
NLS製藥股價上漲，公司宣佈其非磺胺類、雙奧雷欣受體激動劑的臨床前數據，用於治療嗜睡症和神經系統疾病。
NLS Pharmaceutics Shares Are Trading Higher After the Company Announced Preclinical Data for Its Non-sulfonamide, Dual Orexin Receptor Agonists for Potential Treatment of Narcolepsy and Neurological Disorders.
NLS藥品股份正因公司宣佈其非磺胺類雙色欣受體激動劑的臨床前數據，用於潛在治療嗜睡症和神經系統疾病，股價上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間